

Everolimus plus exemestane for hormone-receptor-positive  
factor receptor-2-negative advanced breast cancer: overall  
BOLERO-2

Annals of Oncology

25, 2357-2362

DOI: [10.1093/annonc/mdu456](https://doi.org/10.1093/annonc/mdu456)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Progression-free or overall survivalâ€  revisited in BOLERO-2. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 1.	0.1	1
2	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology, 2014, 25, 1871-1888.	0.6	402
3	Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Research and Treatment, 2014, 147, 433-441.	1.1	17
4	Everolimus in the Treatment of Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 2015, 9, BCBCR.S29268.	0.6	42
5	Delaying Chemotherapy in the Treatment of Hormone Receptorâ€Positive, Human Epidermal Growth Factor Receptor 2â€Negative Advanced Breast Cancer. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S31586.	0.6	15
6	The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. BMC Medicine, 2015, 13, 223.	2.3	1
7	Current management of mTOR inhibitor-associated stomatitis. Breast Cancer Management, 2015, 4, 255-264.	0.2	0
8	New generations of targeted therapies fighting the resistance in solid tumors. Current Opinion in Oncology, 2015, 27, 243-249.	1.1	4
9	Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis. Oncotarget, 2015, 6, 44005-44018.	0.8	13
10	Current medical treatment of estrogen receptor-positive breast cancer. World Journal of Biological Chemistry, 2015, 6, 231.	1.7	144
11	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 541-552.	12.5	121
12	Optimizing the Use of Neoadjuvant Endocrine Therapy. Current Oncology Reports, 2015, 17, 33.	1.8	2
13	Clinical Trial Ethics: One Standard Does Not Fit All. Journal of Clinical Oncology, 2015, 33, 1413-1413.	0.8	2
14	Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care, 2015, 10, 168-172.	0.8	19
15	A call back to reality!. Nature Reviews Clinical Oncology, 2015, 12, 67-68.	12.5	3
16	Management of locally advanced breast cancerâ€perspectives and future directions. Nature Reviews Clinical Oncology, 2015, 12, 147-162.	12.5	113
17	Mechanisms of hormonal therapy resistance in breast cancer. International Journal of Clinical Oncology, 2015, 20, 262-267.	1.0	14
18	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2â advanced breast cancer. Cancer Treatment Reviews, 2015, 41, 94-104.	3.4	22

#	ARTICLE	IF	CITATIONS
19	Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 823-834.	1.5	3
20	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology, 2015, 17, 1261-1269.	0.6	126
21	Adjuvant systemic therapy in breast cancer: quo vadis?. Annals of Oncology, 2015, 26, 1629-1634.	0.6	18
22	Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2. Biochemical Pharmacology, 2015, 96, 306-314.	2.0	9
24	Surgery in the era of the 'omics revolution. British Journal of Surgery, 2015, 102, e29-e40.	0.1	9
25	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncology, The, 2015, 16, 816-829.	5.1	261
26	Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer. Current Oncology, 2015, 22, 33-48.	0.9	95
27	The Strength of Association Between Surrogate End Points and Survival in Oncology. JAMA Internal Medicine, 2015, 175, 1389.	2.6	287
28	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. Oncologist, 2015, 20, 719-724.	1.9	46
29	Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines. Current Oncology, 2015, 22, 29-42.	0.9	18
30	Soy and Breast Cancer: Focus on Angiogenesis. International Journal of Molecular Sciences, 2015, 16, 11728-11749.	1.8	149
31	Influence of censoring on conclusions of trials for women with metastatic breast cancer. European Journal of Cancer, 2015, 51, 721-724.	1.3	16
32	Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer, 2015, 15, 261-275.	12.8	319
34	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Medicine, 2015, 13, 46.	2.3	27
35	Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome. Breast Cancer Research and Treatment, 2015, 150, 473-478.	1.1	16
36	Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. Neoplasia, 2015, 17, 279-288.	2.3	56
37	Chemotherapy for Metastatic Breast Cancer — An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe Und Frauenheilkunde, 2015, 75, 574-583.	0.8	19
38	Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study. Breast, 2015, 24, 718-722.	0.9	8

#	ARTICLE	IF	CITATIONS
39	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 287-297.	1.1	26
40	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , 2015, 42, 887-895.	0.8	45
41	Optimal management of hormone receptor positive metastatic breast cancer in 2016. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 304-320.	1.4	104
42	Targeted therapies for ER+/HER2- metastatic breast cancer. <i>BMC Medicine</i> , 2015, 13, 137.	2.3	59
43	The role of censoring on progression free survival: Oncologist discretion advised. <i>European Journal of Cancer</i> , 2015, 51, 2269-2271.	1.3	18
44	Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 885-891.	1.1	12
45	Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 286-294.	0.9	5
46	Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv212.	3.0	79
47	Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast. <i>Seminars in Oncology</i> , 2015, 42, e81-e94.	0.8	7
48	Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Cancer Management and Research</i> , 2016, Volume 8, 85-94.	0.9	12
49	Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Cancer Management and Research</i> , 2016, Volume 8, 127-128.	0.9	1
50	Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. <i>Oncotarget</i> , 2016, 7, 54120-54136.	0.8	23
51	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. <i>Ecancermedalscience</i> , 2016, 10, 609.	0.6	30
52	Recent advances in the medical treatment of breast cancer. <i>F1000Research</i> , 2016, 5, 2786.	0.8	10
53	Chasing Certainty: Issues of Evidence and Value in Cancer Care. <i>Journal of Oncology Practice</i> , 2016, 12, 1195.	2.5	1
54	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e40-e54.	1.8	29
55	An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299.	0.3	2
56	The Changing Landscape of Breast Cancer: How Biology Drives Therapy. <i>Medicines (Basel, Switzerland)</i> , 2016, 3, 2.	0.7	11

#	ARTICLE	IF	CITATIONS
57	Surrogate end points for overall survival in breast cancer trials: A review. <i>Breast</i> , 2016, 29, 44-48.	0.9	11
58	Safety of everolimus plus exemestane in patients with hormone-receptorâ€‘positive, HER2â€‘negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). <i>Annals of Oncology</i> , 2016, 27, 1719-1725.	0.6	64
59	Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000620.	0.5	5
60	Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. <i>BMC Research Notes</i> , 2016, 9, 497.	0.6	11
61	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology, The</i> , 2016, 17, e560-e567.	5.1	74
62	Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 144, 487-537.	0.9	29
63	Everolimusâ€‘induced tubular toxicity in nonâ€‘renal cancer. <i>Internal Medicine Journal</i> , 2016, 46, 1454-1455.	0.5	4
64	BET Bromodomain Proteins as Cancer Therapeutic Targets. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 123-129.	2.0	56
65	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	1.0	102
66	Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8 <sup>+</sup> effector T cell responses. <i>Oncolmmunology</i> , 2016, 5, e1146841.	2.1	21
67	AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models. <i>Cancer Research</i> , 2016, 76, 3307-3318.	0.4	151
68	A Review of Local and Systemic Therapy in Breast Cancer. , 2016, , 731-764.		0
69	Endocrine Therapy for Hormone Receptorâ€‘Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3069-3103.	0.8	456
70	Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer. <i>Bone</i> , 2016, 87, 169-175.	1.4	16
71	Safety of mTOR inhibitors in breast cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1075-1085.	1.0	6
72	Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1039-1041.	0.9	0
73	Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 925-935.	1.0	67
74	Balancing Accelerated Approval for Drugs With Accelerated Withdrawalâ€‘Reply. <i>JAMA Internal Medicine</i> , 2016, 176, 567.	2.6	0

#	ARTICLE	IF	CITATIONS
75	Cancer drug related cardiotoxicity during breast cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 1063-1074.	1.0	12
76	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 811-821.	5.1	239
77	Pushing estrogen receptor around in breast cancer. Endocrine-Related Cancer, 2016, 23, T227-T241.	1.6	35
78	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discovery, 2016, 6, 1090-1105.	7.7	217
79	Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocrine-Related Cancer, 2016, 23, R337-R352.	1.6	95
80	Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Oncologist, 2016, 21, 922-930.	1.9	10
81	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 3-18.	0.7	8
82	Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. JAMA Oncology, 2016, 2, 1310.	3.4	395
83	Endocrine treatment in breast cancer: Cure, resistance and beyond. Cancer Treatment Reviews, 2016, 50, 68-81.	3.4	114
84	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 2179-2189.	0.9	9
85	Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. Current Problems in Cancer, 2016, 40, 95-105.	1.0	18
86	Metastatic breast cancer: The Odyssey of personalization. Molecular Oncology, 2016, 10, 1147-1159.	2.1	19
87	Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer. European Journal of Cancer, 2016, 69, 216-222.	1.3	15
88	Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S32813.	0.6	41
89	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S12443.	0.6	8
90	The therapeutic potential of mTOR inhibitors in breast cancer. British Journal of Clinical Pharmacology, 2016, 82, 1189-1212.	1.1	93
91	Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015. Seminars in Radiation Oncology, 2016, 26, 59-70.	1.0	11
92	Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. Clinical Breast Cancer, 2016, 16, 188-195.	1.1	11

#	ARTICLE	IF	CITATIONS
93	Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 18-22.	1.1	22
94	Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. <i>Drug Resistance Updates</i> , 2016, 24, 13-22.	6.5	31
95	“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 3-18.	6.6	399
96	FOXO factors and breast cancer: outfoxing endocrine resistance. <i>Endocrine-Related Cancer</i> , 2016, 23, R113-R130.	1.6	39
97	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 31-49.	1.9	35
98	mTORC1 directly phosphorylates and activates ER $\alpha$ upon estrogen stimulation. <i>Oncogene</i> , 2016, 35, 3535-3543.	2.6	70
99	Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 348-355.	0.8	30
100	Targeting the Breast Cancer Kinome. <i>Journal of Cellular Physiology</i> , 2017, 232, 53-60.	2.0	23
101	New oral targeted therapies for metastatic breast cancer disrupt the traditional patients’ management-A healthcare providers’ view. <i>European Journal of Cancer Care</i> , 2017, 26, e12624.	0.7	4
102	Breast Cancer Metastasis. , 2017, , 13-31.		9
103	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. , 2017, 175, 91-106.		167
104	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 297-310.	1.1	3
105	Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 55, 16-25.	3.4	18
106	The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 6.	1.3	44
107	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 439-450.	1.1	47
108	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 91-101.	2.0	15
109	Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. <i>Annals of Oncology</i> , 2017, 28, 1825-1831.	0.6	47
110	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. <i>Npj Breast Cancer</i> , 2017, 3, 3.	2.3	17

#	ARTICLE	IF	CITATIONS
111	Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. <i>Future Oncology</i> , 2017, 13, 1371-1384.	1.1	5
112	New agents for endocrine resistance in breast cancer. <i>Breast</i> , 2017, 34, 1-11.	0.9	22
113	A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 290-301.	0.3	11
114	Do patient access schemes for high-cost cancer drugs deliver value to society?â€”lessons from the NHS Cancer Drugs Fund. <i>Annals of Oncology</i> , 2017, 28, 1738-1750.	0.6	102
115	3rd ESOâ€”ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017, 28, 16-33.	0.6	865
116	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
117	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	1.2	34
118	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2âˆ” Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5218-5224.	3.2	492
119	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 335-346.	1.4	39
120	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 525-536.	0.5	0
121	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 585-594.e4.	1.1	39
122	Phase I Trial of Everolimus and Capecitabine in Metastatic HER2 âˆ” Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 418-426.	1.1	5
123	Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2017, 22, 507-517.	1.9	27
124	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2403-2414.	6.3	168
125	Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. <i>British Journal of Cancer</i> , 2017, 116, 10-20.	2.9	13
126	3rd ESOâ€”ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017, 31, 244-259.	0.9	171
127	Advances in chemical pharmacotherapy to manage advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 95-103.	0.9	4
128	New Strategies in Metastatic Hormone Receptorâ€”Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. <i>Clinical Cancer Research</i> , 2017, 23, 1126-1131.	3.2	11



#	ARTICLE	IF	CITATIONS
130	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. Breast Care, 2017, 12, 290-294.	0.8	21
131	Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. European Journal of Cancer, 2017, 85, 146-154.	1.3	29
132	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012â€“2035). Cancer Treatment Reviews, 2017, 60, 12-17.	3.4	15
133	Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 465-479.	1.4	46
134	Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. Therapeutic Advances in Medical Oncology, 2017, 9, 693-709.	1.4	32
135	Endocrine Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 557-568.		0
136	Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?. Future Oncology, 2017, 13, 1361-1364.	1.1	0
137	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treatment Reviews, 2017, 59, 22-32.	3.4	38
138	Treatment for the endocrine resistant breast cancer: Current options and future perspectives. Journal of Steroid Biochemistry and Molecular Biology, 2017, 172, 166-175.	1.2	41
139	Targeting the mTOR pathway in breast cancer. Tumor Biology, 2017, 39, 101042831771082.	0.8	20
140	Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations. Oncology, 2017, 93, 143-156.	0.9	7
141	Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. Cancer Letters, 2017, 384, 27-38.	3.2	19
142	Breast cancer. Lancet, The, 2017, 389, 1134-1150.	6.3	1,568
143	Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2â€“ Advanced Breast Cancer. Oncologist, 2017, 22, 12-24.	1.9	14
144	Over-treatment in metastatic breast cancer. Breast, 2017, 31, 309-317.	0.9	25
145	Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormoneâ€“Responsive Human Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2063-2074.	2.0	38
146	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. Cancer Treatment Reviews, 2017, 52, 33-40.	3.4	75
147	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ: British Medical Journal, 2017, 359, j4530.	2.4	423

#	ARTICLE	IF	CITATIONS
148	New agents for the management of resistant metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1815-1831.	0.9	5
149	Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer. Journal of Breast Cancer, 2017, 20, 321.	0.8	21
150	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Medicine, 2017, 15, 134.	2.3	169
151	The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review. Oncotarget, 2017, 8, 95023-95029.	0.8	8
152	Drug discovery targeting the mTOR pathway. Clinical Science, 2018, 132, 543-568.	1.8	65
154	Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clinical Cancer Research, 2018, 24, 2452-2463.	3.2	32
155	Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer. Cancer Treatment and Research, 2018, 173, 141-154.	0.2	13
156	Annals of Oncology: factors for making a real impact. Annals of Oncology, 2018, 29, 28-29.	0.6	2
157	Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 2018, 63, 144-155.	3.4	26
158	Adjuvant Endocrine Therapy. , 2018, , 736-751.e4.		2
159	Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6.		2
160	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
161	Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. European Journal of Cancer, 2018, 91, 38-46.	1.3	17
162	Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-“positive and Human Epidermal Growth Factor Receptor 2”-negative Metastatic Breast Cancer in Japan. Pharmacoeconomics, 2018, 36, 1113-1124.	1.7	4
163	An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609.	0.9	1
164	Acquired resistance to aromatase inhibitors: where we stand!. Endocrine-Related Cancer, 2018, 25, R283-R301.	1.6	74
165	Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. Digestion, 2018, 97, 275-287.	1.2	17
166	Patient Case Lessons: Endocrine Management of Advanced Breast Cancer. Clinical Breast Cancer, 2018, 18, 192-204.	1.1	7

#	ARTICLE	IF	CITATIONS
167	Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. <i>Clinical Breast Cancer</i> , 2018, 18, e41-e47.	1.1	9
168	Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. <i>Breast Cancer</i> , 2018, 25, 392-401.	1.3	134
170	Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. <i>Clinical Cancer Research</i> , 2018, 24, 395-406.	3.2	18
171	New Treatments for Metastatic Breast Cancer. , 2018, , 167-197.		0
172	Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-Âmetastatic breast cancer. <i>Future Oncology</i> , 2018, 14, 537-544.	1.1	14
173	Molecular Diagnosis and Targeting Therapy for Breast Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 33-47.	0.1	0
174	Dosing time dependent <i>in vitro</i> pharmacodynamics of Everolimus despite a defective circadian clock. <i>Cell Cycle</i> , 2018, 17, 33-42.	1.3	21
175	Results From a Health Insurer's Clinical Pathway Program in Breast Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e711-e721.	2.5	8
176	Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. <i>Oncotarget</i> , 2018, 9, 8810-8822.	0.8	15
177	Everolimus-induced pulmonary toxicity. <i>Medicine (United States)</i> , 2018, 97, e12518.	0.4	5
178	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor -Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	0.8	134
179	Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 494-502.	0.5	2
180	Disease or not, aging is easily treatable. <i>Aging</i> , 2018, 10, 3067-3078.	1.4	47
181	Management of Hormone Receptor-Positive Metastatic Breast Cancer. , 0, , .		0
182	Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells. <i>Oncotarget</i> , 2018, 9, 23451-23461.	0.8	7
183	Novel Agents for the Management of Endocrine Resistant Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 274-281.	0.5	0
184	Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer. <i>Oncotarget</i> , 2018, 9, 21468-21477.	0.8	12
185	Value Assessment in Oncology Drugs: Funding of Drugs for Metastatic Breast Cancer in Canada. <i>Current Oncology</i> , 2018, 25, 161-170.	0.9	9

#	ARTICLE	IF	CITATIONS
186	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240.	0.8	20
187	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	1.3	53
188	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). <i>Journal of Breast Cancer</i> , 2018, 11, 101-107.	0.4	10
189	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	2.2	48
190	Advances in the use of PARP inhibitor therapy for breast cancer. <i>Drugs in Context</i> , 2018, 7, 1-30.	1.0	101
191	Signaling pathways and steroid receptors modulating estrogen receptor function in breast cancer. <i>Genes and Development</i> , 2018, 32, 1141-1154.	2.7	107
192	Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 51-61.	1.2	29
193	Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1367.	3.4	67
194	Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. <i>JAAD Case Reports</i> , 2018, 4, 452-454.	0.4	17
195	Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. <i>Oncologist</i> , 2018, 23, 974-981.	1.9	19
196	Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 14.	2.3	10
197	Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. <i>Nature Chemical Biology</i> , 2018, 14, 768-777.	3.9	64
198	Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Current Oncology</i> , 2018, 25, 18-27.	0.9	96
199	Everolimus-based combination therapies for HR+, HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 69, 204-214.	3.4	48
200	Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 80.	6.9	36
201	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018, 8, 161.	1.3	123
202	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	0.6	891
203	Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. <i>Current Oncology</i> , 2018, 25, 131-141.	0.9	31

#	ARTICLE	IF	CITATIONS
204	The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 215-228.	4.9	36
205	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 63-70.	3.4	79
206	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 308.	1.3	62
207	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. <i>Annals of Translational Medicine</i> , 2018, 6, 163-163.	0.7	86
208	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14
209	The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 285-308.	1.7	47
210	mTOR signalling: jack-of-all-trades. <i>Biochemistry and Cell Biology</i> , 2019, 97, 58-67.	0.9	19
211	Fasting and rapamycin: diabetes versus benevolent glucose intolerance. <i>Cell Death and Disease</i> , 2019, 10, 607.	2.7	51
212	EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. <i>Future Oncology</i> , 2019, 15, 3209-3218.	1.1	43
213	Targeting mTOR for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 71.	6.9	542
214	Treating HR+/HER2 <sup>-</sup> breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	1.1	29
215	Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Drugs</i> , 2019, 79, 1849-1866.	4.9	36
216	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
217	The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2 <sup>-</sup> Metastatic Breast Cancer: Biological Mechanisms and New Treatments. <i>Cancers</i> , 2019, 11, 1242.	1.7	68
218	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019, 21, 108.	2.2	21
219	Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy. <i>Cancers</i> , 2019, 11, 1465.	1.7	50
220	Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer. <i>Breast Cancer</i> , 2019, 26, 748-757.	1.3	1
221	Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. <i>BMC Cancer</i> , 2019, 19, 491.	1.1	42

#	ARTICLE	IF	CITATIONS
222	Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1607-1618.	2.5	18
223	Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 495-506.	1.1	7
224	Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e8-e21.	1.8	22
225	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	1.1	26
226	Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. <i>Cancer Medicine</i> , 2019, 8, 1943-1957.	1.3	26
227	Tucidinosat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 806-815.	5.1	154
228	C-6 $\beta$ - vs C-7 $\beta$ -Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3636-3657.	2.9	25
229	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
230	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	1.8	406
231	Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2019, 58, 385-387.	0.8	2
232	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. <i>Oncologist</i> , 2019, 24, 1153-1158.	1.9	9
233	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. <i>Cancers</i> , 2019, 11, 1894.	1.7	53
234	Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	0.8	11
236	CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer. <i>Medicine (United States)</i> , 2019, 98, e13909.	0.4	4
237	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER + breast cancer. <i>FASEB Journal</i> , 2019, 33, 1644-1657.	0.2	13
238	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
239	Overcoming Endocrine Resistance in Breast Cancer. , 2019, , 393-422.		2
240	Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours – the MACBETH project. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 301-318.	1.1	1

#	ARTICLE	IF	CITATIONS
241	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351.	1.2	28
242	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45.	1.2	14
243	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. <i>Breast</i> , 2019, 44, 46-51.	0.9	2
244	Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. <i>Breast</i> , 2019, 43, 1-6.	0.9	12
245	Treatment of advanced HR+/HER2 <sup>-</sup> breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. <i>Acta Oncol<sup>3</sup>gica</i> , 2019, 58, 147-153.	0.8	7
246	Decision Pathways in Breast Cancer Management. , 2019, , 3-97.		0
247	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9
248	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
249	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. <i>Breast Care</i> , 2020, 15, 408-414.	0.8	13
250	Oral Complications. , 2020, , 607-620.e6.		0
251	Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. <i>Current Heart Failure Reports</i> , 2020, 17, 397-408.	1.3	12
252	The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. <i>Medicina (Lithuania)</i> , 2020, 56, 348.	0.8	3
253	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	1.4	55
254	Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. <i>Breast Care</i> , 2020, 15, 347-354.	0.8	46
255	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor <sup>+</sup> positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6141-6148.	3.2	6
256	Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians. <i>Cancers</i> , 2020, 12, 2390.	1.7	21
257	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. <i>ESMO Open</i> , 2020, 5, e000842.	2.0	16
258	Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. <i>Theranostics</i> , 2020, 10, 10360-10377.	4.6	30

#	ARTICLE	IF	CITATIONS
259	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342094486.	0.6	20
260	Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096725.	1.4	0
261	Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study. <i>Frontiers in Oncology</i> , 2020, 10, 580112.	1.3	37
262	Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2 <sup>-</sup> Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , 2020, 10, 291.	1.1	4
263	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2020, 15, 723-732.	1.7	6
264	Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 1099-1108.	0.9	17
265	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. <i>Breast Cancer</i> , 2020, 27, 973-981.	1.3	4
266	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308.	1.8	3
267	Breast Cancer Survivorship, Quality of Life, and Late Toxicities. <i>Frontiers in Oncology</i> , 2020, 10, 864.	1.3	121
268	Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. <i>EClinicalMedicine</i> , 2020, 21, 100332.	3.2	80
269	Palbociclib and beyond for the treatment of HR <sup>+</sup> /HER2 <sup>-</sup> metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. <i>Current Medical Research and Opinion</i> , 2020, 36, 1363-1373.	0.9	5
270	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor <sup>+</sup> Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. <i>Clinical Cancer Research</i> , 2020, 26, 5172-5177.	3.2	82
271	Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 945-954.	1.0	11
272	Individualized Prediction of Survival Benefit From Locoregional Surgical Treatment for Patients With Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 148.	1.3	13
273	Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1199.	1.8	52
274	Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 581-587.	3.2	60
275	Flawed trials for cancer. <i>Annals of Oncology</i> , 2020, 31, 331-333.	0.6	5
276	Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1364-1377.	1.2	1



#	ARTICLE	IF	CITATIONS
277	c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis. <i>Targeted Oncology</i> , 2020, 15, 139-146.	1.7	5
278	Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. <i>Cancer Medicine</i> , 2020, 9, 4527-4539.	1.3	7
279	The Landscape of Targeted Therapies in TNBC. <i>Cancers</i> , 2020, 12, 916.	1.7	232
280	Informative censoring – a neglected cause of bias in oncology trials. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 327-328.	12.5	43
281	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020, 22, 33.	2.2	26
282	Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 235-237.	0.5	2
283	<sup>18</sup> F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2 <sup>-</sup> Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190.	2.8	20
284	A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 139-152.	1.5	5
285	Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. <i>Oncologist</i> , 2021, 26, 101-106.	1.9	28
286	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136.	1.3	23
287	SOLAR1s: alpelisib returns to earth?. <i>Annals of Oncology</i> , 2021, 32, 129-132.	0.6	2
288	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2
289	Autophagy-mediated tumor cell survival and progression of breast cancer metastasis to the brain. <i>Journal of Cancer</i> , 2021, 12, 954-964.	1.2	20
290	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(âˆ-) breast cancer receiving salvage treatment with everolimus/exemestane. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 277-287.	1.1	5
291	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. <i>Breast Care</i> , 2021, 16, 115-128.	0.8	10
292	Molecular Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer in Clinical Practice. <i>Journal of Nippon Medical School</i> , 2022, 89, 88-94.	0.3	0
293	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	2.2	15
294	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18

#	ARTICLE	IF	CITATIONS
295	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644737.	1.3	70
297	Advances in epigenetic therapeutics with focus on solid tumors. <i>Clinical Epigenetics</i> , 2021, 13, 83.	1.8	53
298	ESMO pays tribute to Professor JosÃ© Baselga. <i>Immuno-Oncology Technology</i> , 2021, , 100027.	0.2	0
299	SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. <i>Npj Breast Cancer</i> , 2021, 7, 40.	2.3	9
300	Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer. <i>Current Chemical Biology</i> , 2021, 15, 69-84.	0.2	1
302	Final results of the randomized phase 2 <sc>LEO</sc> trial and bone protective effects of everolimus for premenopausal hormone receptorâ€positive, <sc>HER2</sc>â€negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	2.3	5
303	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822.	0.9	24
304	Breast cancer. <i>Lancet, The</i> , 2021, 397, 1750-1769.	6.3	731
305	ESMO pays tribute to Professor JosÃ© Baselga. <i>ESMO Open</i> , 2021, , 100130.	2.0	0
306	Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2929-2939.	1.0	3
307	Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors. <i>Breast Care</i> , 2022, 17, 1-8.	0.8	2
308	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7
309	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 469-477.	1.3	5
310	Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e000082.	1.6	55
311	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	2.0	37
312	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6
313	Evolution of overall survival and receipt of new therapies by subtype among 20â€™446 metastatic breast cancer patients in the 2008-2017 ESME cohort. <i>ESMO Open</i> , 2021, 6, 100114.	2.0	50
314	Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). <i>Oncologist</i> , 2021, 26, e1693-e1703.	1.9	35

#	ARTICLE	IF	CITATIONS
315	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 1-9.	1.1	6
316	Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer. <i>Cancers</i> , 2021, 13, 3254.	1.7	10
317	ESMO pays tribute to Professor JosÃ© Baselga. <i>Annals of Oncology</i> , 2021, 32, 823-824.	0.6	0
318	Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258.	0.8	4
319	Sequential anticancer therapy in a patient with metachronous primary uterine cancer and breast cancer. <i>Malignant Tumours</i> , 2021, 10, 38-46.	0.1	1
320	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	2.2	11
321	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
322	Hormonoterapia en cÃ¡ncer de mama metastÃ¡sico. RevisiÃ³n de la Evidencia y Abordaje TerapÃ©utico en el Instituto Nacional de CancerologÃa, BogotÃ - Colombia. <i>Revista Colombiana De CancerologÃa</i> , 0, 25, 142-151.	0.0	0
323	Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer â€œ Proceedings from breast cancer expert group meeting. <i>BMC Proceedings</i> , 2021, 15, 15.	1.8	5
324	Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study. <i>Annals of Translational Medicine</i> , 2021, 9, 1334-1334.	0.7	3
325	Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. <i>JAMA Oncology</i> , 2021, 7, e213428.	3.4	18
326	Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 227-240.	1.1	2
327	Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer. <i>Cancers</i> , 2021, 13, 4808.	1.7	5
328	Combined endocrine and targeted therapy in luminal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1237-1251.	1.1	12
329	Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2â€” Advanced Breast Cancer. <i>Current Oncology</i> , 2021, 28, 491-508.	0.9	5
330	Mechanisms of resistance to mTOR inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102886.	2.0	27
331	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100606.	1.0	11
332	The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. <i>Endocrine-Related Cancer</i> , 2020, 27, R307-R327.	1.6	23

#	ARTICLE	IF	CITATIONS
333	Kinetics, prognostic and predictive values of <i>ESR1</i> circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. <i>Oncotarget</i> , 2016, 7, 74448-74459.	0.8	80
334	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. <i>Oncotarget</i> , 2017, 8, 7598-7613.	0.8	79
335	Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. <i>Oncotarget</i> , 2015, 6, 2407-2420.	0.8	50
336	Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. <i>Oncotarget</i> , 2015, 6, 22081-22097.	0.8	20
337	mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. <i>Oncotarget</i> , 2016, 7, 27055-27066.	0.8	14
338	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016, 7, 40073-40084.	0.8	15
339	Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. <i>Annals of Translational Medicine</i> , 2017, 5, 481-481.	0.7	11
340	Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 284-284.	0.7	7
341	Aromatasehemmer: Eine kritische Bestandsaufnahme. , 0, , .		1
342	Metastatic breast cancer: Endocrine therapy landscape reshaped. <i>Avicenna Journal of Medicine</i> , 2017, 07, 144-152.	0.3	7
343	Cohort Study of Secondary Endocrine Therapy in Metastatic Breast Cancer with a Poor Response to Initial Endocrine Therapy. <i>Journal of Clinical Trials</i> , 2016, 06, .	0.1	2
344	PI3K/Akt/mTOR inhibitors in breast cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 342-54.	1.4	183
345	Metastatic Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 467-479.	0.1	0
346	Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. <i>Clinical Breast Cancer</i> , 2022, 22, 143-148.	1.1	12
347	The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. <i>Clinical Breast Cancer</i> , 2022, 22, 223-234.	1.1	2
348	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	1.3	9
349	Metastatic Breast Cancer. , 2016, , 451-474.		0
350	Systemic Therapy. , 2016, , 335-390.		0

#	ARTICLE	IF	CITATIONS
351	Endocrine Therapy. , 2016, , 323-334.		0
352	Decision Pathways in Breast Cancer Management. , 2016, , 765-801.		0
353	Breast Cancer in Younger Women. , 2016, , 529-564.		0
354	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34.	0.1	0
356	Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptorâ€‘positive metastatic breast cancer â€‘ A retrospective pilot analysis and viewpoint. South Asian Journal of Cancer, 2017, 06, 102-105.	0.2	1
358	Endocrine Therapy of Metastatic Breast Cancer. , 2019, , 533-555.		0
360	Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2019, , 419-447.		0
361	The Unfolded Protein Response as an Integrator of Response to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer. Cancer Drug Discovery and Development, 2019, , 163-180.	0.2	0
362	Tyrosine Kinase Inhibitors. , 2019, , 529-539.		0
363	EvaluaciÃ³n y Manejo del CÃ¡ncer de Mama MetastÃ¡sico, Irresecable o Recurrente: 1er Consenso Nacional del CÃ¡ncer de Mama de la Sociedad PanameÃ±a de OncologÃ­a (SPO). Revista Medica De Panama, 2019, 39, .	0.0	0
364	Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Surgery and Medicine, 0, , .	0.0	1
365	An unusual durable response with palbociclib plus letrozole in hormone receptor positive metastatic breast cancer after multiple lines of therapy. Indian Journal of Cancer, 2020, 57, 348-350.	0.2	0
366	Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer. Oncology & Hematology Review, 2020, 16, 23.	0.2	0
367	Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis. Journal of Breast Cancer, 2020, 23, 460.	0.8	1
368	Pericardial Effusion Caused by an mTOR Inhibitor in a Case of Recurrent Breast Cancer. Nihon Gekakei Rengo Gakkaiishi (Journal of Japanese College of Surgeons), 2020, 45, 209-213.	0.0	0
369	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology, 2021, 32, 1475-1495.	0.6	454
370	First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer. P and T, 2015, 40, 511-20.	1.0	16
371	The effect of multi-supportive nursing on the postoperative rehabilitation of breast cancer patients. American Journal of Translational Research (discontinued), 2021, 13, 7327-7334.	0.0	1

#	ARTICLE	IF	CITATIONS
372	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. <i>Cancers</i> , 2021, 13, 5643.	1.7	16
373	Targeted Therapy in HR+ HER2+ Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. <i>Cancers</i> , 2021, 13, 5994.	1.7	11
374	Molecular Characterization, Via Next-Generation Sequencing, of Refractory or Resistant Invasive Breast Carcinoma. <i>Cureus</i> , 2021, 13, e19528.	0.2	0
376	Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis. <i>MicroRNA (Sharīqah, United Arab)</i> Tj ETQq1 1 0.78434 rgBT4Overloc		
377	Biomarkers of everolimus efficacy in breast cancer therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522110736.	0.5	2
379	SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. <i>Endocrine Oncology</i> , 2022, ,	0.1	0
380	Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead. <i>JAMA Oncology</i> , 2022, 8, 679.	3.4	25
381	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
382	Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 415-436.	1.1	4
383	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
384	Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13512.	1.8	6
385	Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. <i>Cancer Investigation</i> , 2022, 40, 199-209.	0.6	1
386	Lebensqualität und Lebensverlängerung durch endokrin kombinierte Tumorthherapie. <i>Frauenheilkunde Up2date</i> , 2021, 15, 497-513.	0.0	0
387	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24.	1.3	9
390	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 172-199.	0.5	6
391	At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 471-485.	12.5	56
392	Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience. <i>Bulletin Du Cancer</i> , 2022, 109, 723-723.	0.6	1
393	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	0.8	11

#	ARTICLE	IF	CITATIONS
394	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	0.6	37
395	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. <i>Lancet Oncology</i> , The. 2022, 23, 851-864.	5.1	50
397	Breast cancer in the era of precision medicine. <i>Molecular Biology Reports</i> , 2022, 49, 10023-10037.	1.0	19
398	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12
399	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
400	Current treatment aspects of hormone-dependent ERBB2-negative metastatic breast cancer: overall survival outcomes. <i>Journal of Modern Oncology</i> , 2022, 24, 226-233.	0.1	0
401	Exosomes, autophagy and ER stress pathways in human diseases: Cross-regulation and therapeutic approaches. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166484.	1.8	15
402	Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors. <i>Anticancer Research</i> , 2022, 42, 3913-3919.	0.5	4
404	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
405	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
406	CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review). <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	15
407	Breast cancer: an up-to-date review and future perspectives. <i>Cancer Communications</i> , 2022, 42, 913-936.	3.7	70
409	Predicting clinical response to everolimus in ER+ breast cancers using machine-learning. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
410	Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 2007.	1.1	0
411	Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 6100.	1.7	4
412	Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. <i>Biomedicines</i> , 2023, 11, 109.	1.4	18
413	Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?. <i>Journal of Nippon Medical School</i> , 2023, , .	0.3	0
414	Deciphering breast cancer: from biology to the clinic. <i>Cell</i> , 2023, 186, 1708-1728.	13.5	72

#	ARTICLE	IF	CITATIONS
415	The Role of Autophagy in Breast Cancer Metastasis. <i>Biomedicines</i> , 2023, 11, 618.	1.4	3
416	Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
418	Systemic therapy for hormone receptor- $\epsilon$ positive/human epidermal growth factor receptor 2- $\epsilon$ negative early stage and metastatic breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 480-515.	157.7	23
419	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 2015.	1.7	3
420	Second-line Endocrine Therapy of Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis. <i>Current Cancer Drug Targets</i> , 2023, 23, .	0.8	0
421	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. <i>Cancers</i> , 2023, 15, 2204.	1.7	10
440	Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. , 2024, 41, .		1